What is Caribou Biosciences share price today?

Caribou Biosciences (CRBU) share price today is {{live_price}}.

Can Indians buy Caribou Biosciences shares?

Yes, Indians can invest in the Caribou Biosciences (CRBU) from India. With INDmoney, you can buy Caribou Biosciences at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy Caribou Biosciences at zero transaction cost.

How can I buy Caribou Biosciences shares from India?

It is very easy to buy Caribou Biosciences from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Caribou Biosciences be purchased?

Yes, you can buy fractional shares of Caribou Biosciences with INDmoney app.

What are the documents required to start investing in Caribou Biosciences stocks?

To start investing in Caribou Biosciences, You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Caribou Biosciences

Today’s highest price of Caribou Biosciences (CRBU) is {{1_rba_end}}. Today’s lowest price of Caribou Biosciences (CRBU) is {{1_rba_st}}.

What is today's market capitalisation of Caribou Biosciences

Today's market capitalisation of Caribou Biosciences CRBU is 293.3M

What is the 52 Week High and Low Range of Caribou Biosciences

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage Caribou Biosciences is down from its 52 Week High?

Caribou Biosciences (CRBU) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage Caribou Biosciences is up from its 52 Week low?

Caribou Biosciences (CRBU) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of Caribou Biosciences?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of Caribou Biosciences

Dr. Rachel E. Haurwitz Ph.D. is the current Chief Executive Officer (CEO) of Caribou Biosciences.

Home

US Stocks

Caribou Biosciences

Caribou Biosciences (CRBU)

$4.36

-0.11

(-2.46%)▲

Live

Performance

$4.29
$4.55
$4.36
1.61%
Downside
Day's Volatility :5.71%
Upside
4.18%
$4.05
$13.19
$4.36
7.11%
Downside
52 Weeks Volatility :69.29%
Upside
66.94%

Returns

Period	Caribou Biosciences
3 Months	-18.87%
6 Months	-50.17%
1 Year	-48.74%
3 Years	-72.61%

Highlights

Market Capitalization	293.3M
Book Value	$4.54
Dividend Share	0.0
Dividend Yield	0.0%
Earnings Per Share (EPS)	-1.87
Wall Street Target Price	28.43

Profit Margin	0.0%
Operating Margin TTM	-794.21%

Return On Assets TTM	-18.38%
Return On Equity TTM	-33.34%

Revenue TTM	14.7M
Revenue Per Share TTM	0.24
Quarterly Revenue Growth YOY	31.5%
Gross Profit TTM	-68.4M
EBITDA	-114.8M
Diluted Eps TTM	-1.87
Quarterly Earnings Growth YOY	0.0

EPS Estimate Current Year	-1.96
EPS Estimate Next Year	-2.36
EPS Estimate Current Quarter	-0.49
EPS Estimate Next Quarter	-0.5

Analyst Recommendation

Buy

92%Buy

7%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Caribou Biosciences(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast

What analysts predicted

Upside of 552.06%

Current $4.36

Target $28.43

Company Financials

	FY19	Y/Y Change
Revenue	5.8M	-
Net Income	-23.4M	-
Net Profit Margin	-404.82%	-

	FY20	Y/Y Change
Revenue	12.4M	↑ 113.56%
Net Income	-34.3M	↑ 46.42%
Net Profit Margin	-277.55%	↑ 127.27%

	FY21	Y/Y Change
Revenue	9.6M	↓ 22.35%
Net Income	-66.9M	↑ 95.07%
Net Profit Margin	-697.26%	↓ 419.71%

	FY22	Y/Y Change
Revenue	13.9M	↑ 44.31%
Net Income	-99.4M	↑ 48.56%
Net Profit Margin	-717.79%	↓ 20.53%

	Q4 FY21	Q/Q Change
Revenue	-2.9M	↓ 172.77%
Net Income	-18.5M	↓ 11.9%
Net Profit Margin	638.53%	↑ 1165.91%

	Q1 FY22	Q/Q Change
Revenue	2.7M	↓ 192.05%
Net Income	-19.1M	↑ 3.3%
Net Profit Margin	-716.52%	↓ 1355.05%

	Q2 FY22	Q/Q Change
Revenue	4.2M	↑ 57.36%
Net Income	-26.7M	↑ 39.86%
Net Profit Margin	-636.86%	↑ 79.66%

	Q3 FY22	Q/Q Change
Revenue	3.3M	↓ 21.21%
Net Income	-26.6M	↓ 0.19%
Net Profit Margin	-806.75%	↓ 169.89%

	Q4 FY22	Q/Q Change
Revenue	3.7M	↑ 11.78%
Net Income	-27.0M	↑ 1.28%
Net Profit Margin	-731.01%	↑ 75.74%

	Q1 FY23	Q/Q Change
Revenue	3.5M	↓ 5.15%
Net Income	-28.0M	↑ 3.91%
Net Profit Margin	-800.8%	↓ 69.79%

	FY19	Y/Y Change
Total Assets	61.9M	-
Total Liabilities	13.1M	-

	FY20	Y/Y Change
Total Assets	36.0M	↓ 41.8%
Total Liabilities	18.2M	↑ 38.13%

	FY21	Y/Y Change
Total Assets	442.4K	↓ 98.77%
Total Liabilities	54.5K	↓ 99.7%

	FY22	Y/Y Change
Total Assets	373.8K	↓ 15.51%
Total Liabilities	72.9K	↑ 33.67%

	Q4 FY21	Q/Q Change
Total Assets	442.4M	↓ 4.24%
Total Liabilities	54.5M	↓ 5.26%

	Q1 FY22	Q/Q Change
Total Assets	446.0M	↑ 0.82%
Total Liabilities	74.2M	↑ 36.07%

	Q2 FY22	Q/Q Change
Total Assets	421.4M	↓ 5.52%
Total Liabilities	73.5M	↓ 0.97%

	Q3 FY22	Q/Q Change
Total Assets	398.8M	↓ 5.35%
Total Liabilities	74.7M	↑ 1.68%

	Q4 FY22	Q/Q Change
Total Assets	373.8M	↓ 6.28%
Total Liabilities	72.9M	↓ 2.43%

	Q1 FY23	Q/Q Change
Total Assets	347.5M	↓ 7.04%
Total Liabilities	69.2M	↓ 5.08%

	FY19	Y/Y Change
Operating Cash Flow	-32.0M	-
Investing Cash Flow	27.2M	-
Financing Cash Flow	172.0K	-

	FY20	Y/Y Change
Operating Cash Flow	-33.2M	↑ 3.78%
Investing Cash Flow	6.4M	↓ 76.63%
Financing Cash Flow	1.7M	↑ 908.72%

	FY21	Y/Y Change
Operating Cash Flow	-32.5M	↓ 2.1%
Investing Cash Flow	-176.4M	↓ 2872.23%
Financing Cash Flow	433.4M	↑ 24881.5%

	FY22	Y/Y Change
Operating Cash Flow	-91.0M	↑ 179.73%
Investing Cash Flow	-93.2M	↓ 47.14%
Financing Cash Flow	2.1M	↓ 99.51%

	Q4 FY21	Q/Q Change
Operating Cash Flow	-21.4M	↑ 42.91%
Investing Cash Flow	-174.0M	↑ 8913.52%
Financing Cash Flow	460.0K	↓ 99.86%

	Q1 FY22	Q/Q Change
Operating Cash Flow	-21.7M	↑ 1.33%
Investing Cash Flow	-72.1M	↓ 58.55%
Financing Cash Flow	990.0K	↑ 115.22%

	Q2 FY22	Q/Q Change
Operating Cash Flow	-21.9M	↑ 0.92%
Investing Cash Flow	-14.0M	↓ 80.62%
Financing Cash Flow	362.0K	↓ 63.43%

	Q3 FY22	Q/Q Change
Operating Cash Flow	-65.9M	↑ 201.39%
Investing Cash Flow	-8.3M	↓ 40.32%
Financing Cash Flow	2.0M	↑ 454.14%

	Q4 FY22	Q/Q Change
Operating Cash Flow	18.5M	↓ 128.07%
Investing Cash Flow	1.2M	↓ 114.03%
Financing Cash Flow	-1.2M	↓ 161.07%

	Q1 FY23	Q/Q Change
Operating Cash Flow	-27.9M	↓ 251.01%
Investing Cash Flow	20.7M	↑ 1669.49%
Financing Cash Flow	1.6M	↓ 234.04%

Technicals Summary

Sell

Neutral

Buy

Caribou Biosciences is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Caribou Biosciences	1.59%	-50.17%	-48.74%	-72.61%	-72.61%
Moderna, Inc.	-6.6%	-29.55%	-6.79%	114.56%	571.72%
Regeneron Pharmaceuticals, Inc.	-0.63%	0.01%	30.35%	23.26%	140.46%
Novo Nordisk A/s	-5.39%	23.69%	41.34%	146.71%	255.68%
Seagen, Inc.	-2.64%	57.03%	37.37%	30.74%	191.76%
Vertex Pharmaceuticals Incorporated	-3.55%	6.52%	28.06%	22.79%	123.76%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Caribou Biosciences	NA	NA	NA	-1.96	-0.33	-0.18	0.0	4.54
Moderna, Inc.	10.88	10.88	0.0	-1.74	0.27	0.12	0.0	49.12
Regeneron Pharmaceuticals, Inc.	20.15	20.15	9.01	41.59	0.19	0.1	0.0	219.38
Novo Nordisk A/s	41.07	41.07	2.03	4.99	0.84	0.23	0.01	4.44
Seagen, Inc.	NA	NA	18.53	-2.89	-0.23	-0.12	0.0	14.54
Vertex Pharmaceuticals Incorporated	25.51	25.51	0.41	14.57	0.26	0.17	0.0	56.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Caribou Biosciences	Buy	$293.3M	-72.61%	NA	0.0%
Moderna, Inc.	Buy	$47.9B	571.72%	10.88	31.77%
Regeneron Pharmaceuticals, Inc.	Buy	$81.0B	140.46%	20.15	33.81%
Novo Nordisk A/s	Buy	$356.5B	255.68%	41.07	32.47%
Seagen, Inc.	Hold	$36.5B	191.76%	NA	-31.55%
Vertex Pharmaceuticals Incorporated	Buy	$85.1B	123.76%	25.51	35.4%

Institutional Holdings

Partner Fund Management LP
8.17%
BlackRock Inc
7.70%
State Street Corporation
5.47%
Avidity Partners Management LP
4.50%
Rokos Capital Management LLP
4.48%
Vanguard Group Inc
4.25%

Corporate Announcements

Caribou Biosciences Earnings
Caribou Biosciences’s price-to-earnings ratio stands at None
Read More

Organization	Caribou Biosciences
Employees	137
CEO	Dr. Rachel E. Haurwitz Ph.D.
Industry	Services